All In Biotech

NDA 021165 · Organon

Clarinex

Desloratadine · Oral · Histamine-1 Receptor Antagonist

Novel

Last checked: Nov 20, 2026Latest source record: Mar 15, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Dec 21, 2001

Approved uses

1

Original approval plus efficacy supplements

Registered trials

87

28 Phase 3, 4 recruiting

FAERS reports

10,834

8,441 serious, 608 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 17, 2025.

CLARINEX is a histamine-1 (H1) receptor antagonist indicated for: Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 2 years of age and older. ( 1.1 ) Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 6 months of age and older. ( 1.2 ) Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 6 months of age and older. ( 1.3 ) 1.1 Seasonal Allergic Rhinitis CLARINEX ® is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. 1.2 Perennial Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. 1.3 Chronic Idiopathic Urticaria CLARINEX is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older.

Mechanism: Desloratadine is a long-acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2–3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 -receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a radiolabeled tissue distribution study in rats and a radioligand H 1 -receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. The clinical significance of this...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 21, 2001 Original approval · Type 1 - New Molecular Entity NovelReviewLabelLetter
1 products under this application
  • CLARINEX · DESLORATADINE 5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Desloratadine" as an intervention, any sponsor and status, largest first.

All 87 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective630
  • fatigue629
  • nausea607
  • dyspnoea544
  • headache485
  • diarrhoea471
  • dizziness458
  • pruritus445
  • vomiting417
  • rash396
  • off label use357
  • pyrexia333

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004467
2005347
2006311
2007355
2008292
2009283
2010341
2011444
2012459
2013255
2014246
2015425
2016480
2017401
2018628
2019738
2020653
2021516
2022683
2023601
2024764
2025603
2026542

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Clarinex (Desloratadine)

2024 spending

$252K

Beneficiaries

124

457 claims

Per beneficiary

$2,035

$7.99 per unit

View as table
YearSpending
2020$0
2021$6,774
2022$402,646
2023$289,142
2024$252,395

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 190 on PubMed

Sponsor: Organon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.